New and Emerging Biomarkers in Cardiovascular Disease

• Published in: Current diabetes reports Vol. 15; no. 11; p. 88
• Main Authors: Cahill, Leah E., Bertoia, Monica L., Aroner, Sarah A., Mukamal, Kenneth J., Jensen, Majken K.
• Format: Journal Article Book Review
• Language: English
• Published: New York Springer US 01-11-2015; Springer Nature B.V
• Subjects: Animals; Biomarkers - metabolism; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - metabolism; Diabetes; Humans; Inflammation - complications; Inflammation - metabolism; Lipid Metabolism; Macrovascular Complications in Diabetes (VR Aroda and A Getaneh; Medicine; Medicine & Public Health; Risk Factors; Section Editors; Topical Collection on Macrovascular Complications in Diabetes; Cardiovascular disease; Lipids; Biomarker; Inflammation; Coronary heart disease; Glycemia
• ISSN: 1534-4827; 1539-0829
• DOI: 10.1007/s11892-015-0661-y

Cardiovascular disease (CVD) is the most common cause of death and disability worldwide. Therefore, great importance has been placed on the discovery of novel risk factors and metabolic pathways relevant in the prevention and management of CVD. Such research is ongoing and may continue to lead to better risk stratification of individuals and/or the development of new intervention targets and treatment options. This review highlights emerging biomarkers related to lipid metabolism, glycemia, inflammation, and cardiac damage, some of which show promising associations with CVD risk and provide further understanding of the underlying pathophysiology. However, their measurement methodology and assays will require validation and standardization, and it will take time to accumulate evidence of their role in CVD in various population settings in order to fully assess their clinical utility. Several of the novel biomarkers represent intriguing, potentially game-changing targets for therapy.